Trial · NCT07232069
PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
NCT07232069, Phase 3, Recruiting, Duke University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis. Trials, record NCT07232069. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07232069
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
- NCT number
- NCT07232069
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,500 participants, estimated
- Lead sponsor
- Duke University
- Conditions
- Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
- Interventions
- Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
- First posted
- 2025-11-18
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV. | 2 years | Plaque volume in mm3 in each group |
| Secondary | Number of participants with Drug Discontinuation | Up to 2 years | Drug Tolerability outcome |
| Secondary | Overall drug treatment adherence | Up to 2 years | Number of days on study drugs |
| Secondary | Safety events of special interest | Up to 2 years | Number of safety events of special interest per group |
| Secondary | Total plaque volume | Up to 2 years | Plaque volume in mm3 per group |
| Secondary | Low-attenuation plaque volume | Up to 2 years | Low attenuated plaque volume in mm3 per group |
| Secondary | Calcified plaque volume | Up to 2 years | Calcified plaque volume in mm3 per group |
| Secondary | Number of participants with stenosis | Up to 2 years | Number of participants with stenosis per group |
| Secondary | Segment involvement score | Up to 2 years | Average score per group |
| Secondary | Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition | Up to 2 years | Number of participants with each plaque composition description per group |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UG3HL181434 | 1/2 PREEMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis | PAGIDIPATI, NEHA JADEJA; ALEXANDER, KAREN P; DOUGLAS, PAMELA SUSAN | DUKE UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07232069
GET https://conductscience.org/api/trials/v1/NCT07232069/registered